ArticlePloS one2026
Association between uric acid and non-alcoholic fatty liver disease in patients with hypertension.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum uric acid (UA) is linked to non-alcoholic fatty liver disease (NAFLD), but its role in hypertensive populations remains unclear. This cross-sectional study investigated their association in 1,058 patients with hypertension. Multivariate logistic regression analysis confirmed that UA was independently correlated with NAFLD, whether as a continuous variable or a categorical variable. According to the fully adjusted model, the risk of NAFLD increased by 0.2%, 347.2% and 91.7% for each unit increase in UA, Log10UA and LnUA, respectively (P < 0.05). Multivariate stratified analysis revealed that UA increased the risk of NAFLD in specific subgroups, including males, individuals aged 70-79 years, non-smokers, those without diabetes, and obese individuals (P < 0.05). Receiver operating characteristic (ROC) analysis indicated that UA could not only predict the occurrence of NAFLD but also improve the predictive value of the baseline model for NAFLD (UA, AUC: 0.588; baseline model, AUC: 0.770; baseline model + UA, AUC: 0.772). In conclusion, UA is significantly associated with NAFLD in patients with hypertension and may serve as a predictive risk indicator.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.